主要观点晶泰控股是全球稀缺的AI辅助创新药研发公司,公司AI能力主要体现在两方面:一是AI模型用于创新药(小分子、大分子、多肽、mRNA等领域)及材料(消费品材料及化工新材料)研发,通过超过200个垂直领域的AI模型对海量生物医学、化学数据进行高效挖掘,对蛋白结构及分子性质实现精准预测,以及对药化反应的反应条件及反应路径进行智能规划和结果预测,其研发效率较经验筛选的传统模式实现显著提升,大幅缩短了...
Source Link主要观点晶泰控股是全球稀缺的AI辅助创新药研发公司,公司AI能力主要体现在两方面:一是AI模型用于创新药(小分子、大分子、多肽、mRNA等领域)及材料(消费品材料及化工新材料)研发,通过超过200个垂直领域的AI模型对海量生物医学、化学数据进行高效挖掘,对蛋白结构及分子性质实现精准预测,以及对药化反应的反应条件及反应路径进行智能规划和结果预测,其研发效率较经验筛选的传统模式实现显著提升,大幅缩短了...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.